Shares of Ardelyx Inc (NASDAQ:ARDX) have received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.00.
Several equities analysts recently issued reports on ARDX shares. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Piper Jaffray Companies set a $20.00 target price on Immunomedics and gave the stock a “buy” rating in a research note on Monday, April 8th.
In related news, CEO Michael Raab sold 10,054 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $2.54, for a total transaction of $25,537.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 18,787 shares of company stock worth $47,753. 15.31% of the stock is owned by corporate insiders.
ARDX opened at $2.50 on Wednesday. The business’s 50-day moving average price is $2.62. Ardelyx has a 12-month low of $1.60 and a 12-month high of $4.60. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 0.58.
Ardelyx (NASDAQ:ARDX) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.03). Equities analysts forecast that Ardelyx will post -1.52 earnings per share for the current year.
Ardelyx Company Profile
Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Featured Article: How is a management fee different from a performance fee?
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.